Review of tadalafil in the treatment of erectile dysfunction
Author: Meuleman E.J.
Source: Expert Opinion on Pharmacotherapy, Volume 4, Number 11, 1 November 2003 , pp. 2049-2056(8)
Publisher: Informa Healthcare
Abstract:
Approximately 150 million men worldwide experience erectile dysfunction (ED) whereby they are unable to achieve and maintain an erection adequate for satisfactory sexual performance. ED has a considerable impact on quality of life. Tadalafil (Cialis, Eli Lilly & Co./ICOS) is a novel effective and safe phosphodiesterase type 5 inhibitor, a secondary messenger for the smooth muscle relaxing effects of nitric oxide, which plays a central role in the vasodilation of erectile tissues. It has a longer half-life than sildenafil. As head-to-head comparative trials are lacking, it is not clear what tadalafil offers over sildenafil. In terms of marketing, much is made of the spontaneity achievable because of the (relatively) longer half-life of tadalafil.Keywords: erectile dysfunction; phosphodiesterase type 5 inhibition; tadalafil; treatment
Document Type: Drug Evaluation
Publication date: 2003-11-01
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- ingentaconnect is not responsible for the content or availability of external websites
- In this: publication
- By this: publisher
- In this Subject: Pharmacology
- By this author: Meuleman E.J.

Shopping cart
Receive new issue alert